Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026)

Longeveron (LGVN) recorded quarterly Total Non-Current Liabilities of $838000.0 in Q1 2026, up 67.94% quarter-over-quarter from $499000.0 in Q4 2025, and down 13.25% on a YoY basis from $966000.0 in Q1 2025.

Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends

Longeveron's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $838000.0 for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities fell 13.25% year-over-year to $838000.0; the TTM figure through Mar 2026 stood at $838000.0 (down 13.25% YoY), while the FY2025 annual figure was $499000.0, down 54.18% from the prior year.
  • Total Non-Current Liabilities was $838000.0 for Q1 2026 at Longeveron, up from $499000.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $2.0 million in Q4 2022 to a low of $499000.0 in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged $1.2 million across 5 years, with a median of $1.2 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities slumped 54.18% in 2025, then dropped 13.25% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $2.0 million in 2022, then slipped by 29.05% to $1.4 million in 2023, then dropped by 24.79% to $1.1 million in 2024, then plunged by 54.18% to $499000.0 in 2025, then surged by 67.94% to $838000.0 in 2026.
  • The last three Total Non-Current Liabilities figures came in at $838000.0 (Q1 2026), $499000.0 (Q4 2025), and $651000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 838,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 838,000.00
Dec 31, 2025 499,000.00
Sep 30, 2025 651,000.00
Jun 30, 2025 809,000.00
Mar 31, 2025 966,000.00
Dec 31, 2024 1.09 Mn
Sep 30, 2024 1.18 Mn
Jun 30, 2024 1.27 Mn
Mar 31, 2024 1.36 Mn
Dec 31, 2023 1.45 Mn
Sep 30, 2023 1.60 Mn
Jun 30, 2023 1.75 Mn
Dec 31, 2022 2.04 Mn